DALLAS, July 24, 2017 -- Texas Capital Bancshares, Inc. (NASDAQ:TCBI), the parent company of Texas Capital Bank, and their board of directors declared a cash dividend of $0.40625 per share of the non-cumulative perpetual preferred stock, Series A, which is traded on the NASDAQ under the symbol “TCBIP”. The Series A Preferred Stock dividend is payable on September 15, 2017, to shareholders of record at the close of business on September 1, 2017.
ABOUT TEXAS CAPITAL BANCSHARES, INC.
Texas Capital Bancshares, Inc. (NASDAQ:TCBI), a member of the Russell 2000® Index and the S&P SmallCap 600®, is the parent company of Texas Capital Bank, a commercial bank that delivers highly personalized financial services to businesses and entrepreneurs. Headquartered in Dallas, the bank has full-service locations in Austin, Dallas, Fort Worth, Houston and San Antonio.
MEDIA & INVESTOR CONTACT Heather Worley, 214.932.6646 [email protected]


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



